Duvelisib Inhibits Serum Factors Associated with iNHL and the TME (DYNAMO™)

Duvelisib Inhibits Serum Factors Associated with CLL and the TME

Duvelisib Inhibits Serum Factors Associated with iNHL and the TME

Duvelisib Inhibits Serine Factors Associated with iNHL and the TME

Key DUO Results

Key DYNADO Results

Methods

Conclusions

References: 1) Comparison of Cytokine and Chemokine Changes in CLL and iNHL. 2) Role of Key Cytokines and Chemokines in the TME. 3) Further investigation of the effects of DUV on TME pharmacodynamic markers is warranted.

Key DUO Results

Key DYNADO Results

For both DUO and DYNADO, serum from patients treated is compared to normal or patients treated with a control agent.

For both DUO and DYNADO, serum from patients treated is compared to normal or patients treated with a control agent.

Comparison of Cytokine and Chemokine Changes in CLL and iNHL

Comparison of Cytokine and Chemokine Changes in CLL and iNHL

Further investigation of the effects of DUV on TME pharmacodynamic markers is warranted.

Duvelisib Inhibits Serum Factors Associated with iNHL and the TME

Duvelisib Inhibits Serum Factors Associated with iNHL and the TME

Duvelisib Inhibits Serum Factors Associated with iNHL and the TME

Duvelisib Inhibits Serum Factors Associated with iNHL and the TME

Conclusions

Comparison of Cytokine and Chemokine Changes in CLL and iNHL

Comparison of Cytokine and Chemokine Changes in CLL and iNHL

Further investigation of the effects of DUV on TME pharmacodynamic markers is warranted.